Modified vaccines targeting new variants of the coronavirus won't require domestic clinical trials if the production process and handling of the shots are similar to those of the original authorized vaccine, the nation’s medicine regulator has said.
Drugmakers would still need to submit data from clinical trials overseas that shows immune response to the variants when they apply for Japanese approval, the Pharmaceuticals and Medical Devices Agency (PMDA) said in a statement this week.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.